RELMADA THERAPEUTICS, INC.
RELMADA THERAPEUTICS, INC.
CORAL GABLES, FL
Loading...
Price History
Market Data
| Market Cap | 53.10M |
| P/E Ratio | - |
| P/B Ratio | 0.61 |
| EPS | - |
| Dividend Yield | - |
| D/E Ratio | 0.09 |
| Current Ratio | 14.62 |
| Currency | USD |
Key Financial Metrics
-
Revenue
-57.39M
Net Income
-
EPS (Diluted)
-88.32M
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-59.10M
Returns & Efficiency
Return on Assets (ROA)
-61.0%
Return on Equity (ROE)
-66.3%
Dividend Yield
-
EPS
-
Financial Health
Total Assets
94.00M
Total Debt
-
Debt to Equity
0.09x
Current Ratio
14.62
Insider Trading
Last 12 months
0
Buys
0
Sells
0
Insiders
Quick Access Filings
10-K
Annual Report
Loading...
10-Q
Quarterly Report
Loading...
8-K
Recent News
Loading...
Company Data Library
Earnings Transcripts
Loading...
Press Releases
Loading...
Filing Sections
Loading...
Company Info
| Industry | Chemicals & Allied Products |
| HQ | CORAL GABLES, FL |
| Fiscal Year | 2025 |
Peers
LILLY ELI & CO
LLY
894.82B
P/E: --
ELI LILLY & CO
LLY
894.82B
P/E: --
533.28B
P/E: --
ABBVIE INC.
ABBV
355.49B
P/E: --
BEIGENE, LTD.
BEIGF
306.50B
P/E: 632.4
BEONE MEDICINES LTD.
BEIGF
306.50B
P/E: 632.4
275.14B
P/E: --
MERCK & CO. INC.
MRK
275.14B
P/E: --
Quick Links
Financial Statistics
Valuation
Market Cap$53.10M
P/E Ratio (TTM)-
Price to Book0.61
EV/Revenue-
EV/EBITDA-
Profitability
Gross Margin-
Operating Margin-
Net Margin-
ROE-66.3%
ROA-61.0%
Leverage & Liquidity
Debt to Equity0.09
Current Ratio14.62
Total Debt-
Total Assets$94.00M
Stockholders' Equity$86.51M
Income Statement (FY 2025)
Revenue-
Gross Profit-
Operating Income$-59.10M
Net Income$-57.39M
EPS (Diluted)-
Cash Flow (FY 2025)
Free Cash Flow$-88.32M
Cash & Equivalents$3.50M
Revenue Growth-
SEC Filings by Category
Insider Trading Activity
Neutral
0 Buys $0
0 Sales $0
0 Exercises $0
Net: $0
| Insider | Title | Date | Type | Shares | Price | Value |
|---|
Company Information
| Business Address | 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES, FL 33134 |
| Phone | N/A |
| Incorporated | NV, US |
| EIN | 455401931 |
| Fiscal Year End | 1231 |
| Shares Outstanding | 7.21M |
| Stockholders' Equity | $86.51M |
| Cash & Equivalents | $3.50M |
Recent Filings
View All
SCHEDULE 13G
Passive Ownership Report
Schedule 13G - passive beneficial ownership
Filed: 2026-05-04
Local
EFFECT
Effectiveness Notice
Notice of effectiveness
Filed: 2026-04-09
Local
424B3
Prospectus (Rule 424b3)
Prospectus filed under Rule 424(b)(3)
Filed: 2026-04-09
Local
PRE 14A
Preliminary Proxy Statement
Preliminary proxy statement for SEC review
Filed: 2026-04-06
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2026-03-19
Local
8-K
Current Report
Report of material events (acquisitions, earnings, executive changes)
Filed: 2026-03-09
Local
SCHEDULE 13G/A
Amended Schedule 13G
Amendment to Schedule 13G
Filed: 2026-02-17
Local
SCHEDULE 13G
Passive Ownership Report
Schedule 13G - passive beneficial ownership
Filed: 2026-02-17
Local
SCHEDULE 13G
Passive Ownership Report
Schedule 13G - passive beneficial ownership
Filed: 2026-02-12
Local
SCHEDULE 13G
Passive Ownership Report
Schedule 13G - passive beneficial ownership
Filed: 2026-02-06
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-11-13
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-08-07
Local
10-Q
Quarterly Report
Quarterly financial report with unaudited statements
Filed: 2025-05-12
Local
DEF 14A
Definitive Proxy Statement
Official proxy statement for shareholder voting
Filed: 2025-04-11
Local
10-K
Annual Report
Comprehensive annual financial report with audited statements
Filed: 2025-03-27
Local
Loading...
Loading management data...
Loading...
Loading board of directors...
Loading...
Loading institutional holders...
Loading...
Loading short interest data...
Financial Charts Annual (10-K)
Interactive financial visualizations
Show:
Revenue & Income Trends
Revenue & Profit
Profit Margins
Balance Sheet Breakdown
Assets Composition
Capital Structure
Cash Flow Analysis
Cash Flow Components
Free Cash Flow
Growth & Performance
Revenue Growth Rate (YoY %)
Key Ratio Trends
Company Profile
General Information
| Company Name | RELMADA THERAPEUTICS, INC. |
| Ticker | RLMD |
| Exchange | -- |
| Sector | Manufacturing |
| Industry | Chemicals & Allied Products |
| Headquarters | CORAL GABLES, FL |
| Fiscal Year | 2025 |
Financial Summary
| Market Cap | 53.10M |
| Revenue | - |
| Net Income | -57.39M |
| P/E Ratio | - |
| EPS | - |
| Net Margin | - |
| ROE | -66.3% |
| Dividend Yield | - |
Insider Transactions
Loading...
My Notes & Files
Personal Notes
Attached Files
Loading...